Brokerages Set Atara Biotherapeutics, Inc. (NASDAQ:ATRA) PT at $16.67

Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) have received an average recommendation of “Moderate Buy” from the five analysts that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $16.67.

ATRA has been the subject of several recent analyst reports. TD Cowen raised shares of Atara Biotherapeutics to a “strong-buy” rating in a research report on Friday, November 29th. Canaccord Genuity Group increased their price target on shares of Atara Biotherapeutics from $13.00 to $21.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th.

Hedge Funds Weigh In On Atara Biotherapeutics

A number of institutional investors have recently added to or reduced their stakes in ATRA. Geode Capital Management LLC boosted its position in Atara Biotherapeutics by 9.5% in the third quarter. Geode Capital Management LLC now owns 46,720 shares of the biotechnology company’s stock valued at $380,000 after buying an additional 4,043 shares in the last quarter. State Street Corp grew its position in Atara Biotherapeutics by 52.3% during the 3rd quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock worth $182,000 after acquiring an additional 7,680 shares during the last quarter. Vestal Point Capital LP increased its holdings in Atara Biotherapeutics by 11.3% in the 3rd quarter. Vestal Point Capital LP now owns 124,677 shares of the biotechnology company’s stock worth $1,014,000 after purchasing an additional 12,677 shares in the last quarter. FMR LLC raised its position in Atara Biotherapeutics by 41.7% in the third quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock valued at $204,000 after purchasing an additional 7,381 shares during the last quarter. Finally, Cubist Systematic Strategies LLC bought a new position in Atara Biotherapeutics in the 2nd quarter valued at approximately $79,000. 70.90% of the stock is currently owned by institutional investors and hedge funds.

Atara Biotherapeutics Trading Up 1.2 %

Shares of ATRA opened at $9.93 on Friday. The stock has a market capitalization of $57.20 million, a PE ratio of -0.39 and a beta of 0.55. The firm’s 50 day moving average is $10.73 and its 200-day moving average is $9.63. Atara Biotherapeutics has a 12 month low of $6.50 and a 12 month high of $39.50.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($2.93) earnings per share for the quarter, beating the consensus estimate of ($3.77) by $0.84. The company had revenue of $40.19 million during the quarter, compared to analyst estimates of $23.00 million. During the same period in the prior year, the firm earned ($16.50) earnings per share. Equities research analysts predict that Atara Biotherapeutics will post -12.12 earnings per share for the current fiscal year.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.